drugset / Trial / NCT00516607

Enzastaurin and Temozolomide in Treating Patients With Primary Gliomas

NCT00516607

Non-randomizedOpen-labelTreatment

Summary

RATIONALE: Enzastaurin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving enzastaurin together with temozolomide may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of enzastaurin when given together with temozolomide in treating patients with primary gliomas.

Timeline

Start
2007-07
Primary completion
2008-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject enzastaurin Small molecule 250 mg Oral
Subject enzastaurin Small molecule 500 mg Oral
Background Temozolomide Small molecule 200 mg/m2 Oral